Decreased interleukin-35 levels are associated with higher risk of pregnancy morbidity in patients with antiphospholipid syndrome.

[1]  Y. Takasaki,et al.  Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis. , 2015, Rheumatology.

[2]  A. Risvanli,et al.  What is the impact of SOCS3, IL-35 and IL17 in immune pathogenesis of recurrent pregnancy loss? , 2015, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[3]  X. Qu,et al.  Human placental trophoblasts express the immunosuppressive cytokine IL-35. , 2013, Human immunology.

[4]  K. Boyd,et al.  The inhibitory cytokine IL-35 contributes to regulatory T-cell function , 2007, Nature.

[5]  I. McInnes,et al.  IL‐35 is a novel cytokine with therapeutic effects against collagen‐induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells , 2007, European journal of immunology.

[6]  A. Coulomb-L'Hermine,et al.  Expression of Epstein-Barr virus-induced gene 3, an interleukin-12 p40-related molecule, throughout human pregnancy: involvement of syncytiotrophoblasts and extravillous trophoblasts. , 2001, The American journal of pathology.

[7]  E. Kieff,et al.  Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Chan Jun-mi,et al.  International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome(APS) , 2008 .